Best Life Sciences Companies in Madison, United States
The 106 best Life Sciences companies in Madison, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Exact Sciences.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Madison
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Exact Sciences Provider of non-invasive molecular diagnostic testing solutions for cancer | $1.9B | 87 mo ago | Acquired | 6,600 6,600 → 5,319 (-19%) | Kevin Conroy Chairman & CEO | SitecoreApple iCloud MailMicrosoft 365+25 | 735 patents Multiplexed nucleic-acid biomarker assays for early cancer detection | — |
| 2 | Cellular Dynamics Human iPSC-derived cells and services for research, drug discovery, and therapy | $130M | 151 mo ago | Acquired | — | James Thomson Founder | — | 520 patents Manufacturing and analytical technologies for advanced cell therapies and engineered immune cells | — |
| 3 | Farcast Biosciences Developer of a system for preserving the tumor microenvironment | $85M | 95 mo ago | Series C | 24 24 → 48 (+100%) | Pradip Majumder Co-Founder | Wix eCommerceWixSentry+16 | — | — |
| 4 | Propeller Health Mobile platform and a sensor for respiratory health management | $64M | 96 mo ago | Acquired | 119 | — | Apple iCloud MailSalesforce DeskSalesforce+7 | — | — |
| 5 | FUJIFILM Cellular Dynamics Provider of induced pluripotent stem cells for cell therapy | $62M | 163 mo ago | Series C | 150 | Takeshi Yamamoto Chairman & CEO | Cart FunctionalityMagentoWordPress+32 | 277 patents Manufacturing, purification, and dosing analytics for therapeutic cell and tissue products | — |
| 6 | NeuWave Medical Microwave ablation system for soft tissue and cancer ablation | $58M | 133 mo ago | Acquired | 112 | Dan Van Der Weide Co-Founder | — | 250 patents Microwave ablation devices with temperature control and visualization for minimally invasive tissue treatment | — |
| 7 | Novelos Therapeutics Developer of drugs for the treatment and diagnosis of cancer | $54M | 148 mo ago | Public | 25 | Jamey Weichert Founder | — | — | — |
| 8 | Perceptive IO AI-powered automated robotic surgery device for dentists | $45M | 10 mo ago | Series B | — | Chris Ciriello Co-Founder & CEO | Craft CMSPHPYii+9 | 22 patents Vehicle safety and autonomous perception sensors integrating IR seat‑belt detection and centralized object detection networks. | — |
| 9 | FluGen Developing innovative influenza vaccines with broad immune response and supra-seasonal protection | $34M | 58 mo ago | Series A | 12 | — | — | 136 patents Influenza vaccine design: mutant strains, immunogenic compositions, and thermostable formulations. | — |
| 10 | Imbed Biosciences Provider of nanotech-based wound care products 48Growth top 32%Funding top 37%Talent top 38%Moat top 39% All 7 signals ▾Growthtop 32% Fundingtop 37% Talenttop 38% Moattop 39% Techtop 44% Marketbottom 33% Globalbottom 32% Growth: Headcount 24 → 35 (+46%) across vintages · Fresh capital in last 24 mo Funding: Raised $34.3M across 18 rounds · 18 rounds over 16 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $34M | 4 mo ago | Series C | 35 35 → 40 (+14%) | Michael Schurr Co-Founder & Chief Medical Officer | WordPress Block EditorCart FunctionalityWordPress+30 | — | — |
| 11 | Scarab Genomics Developer of bioengineered E.coli strains for a range of applications | $26M | 21 mo ago | Funding Raised | 16 | — | — | 148 patents Engineering reduced-genome microbes for high-yield recombinant protein production | — |
| 12 | DNASTAR Provider of software for genomics, structural biology, and clinical research | $22M | 13 mo ago | Funding Raised | 41 41 → 26 (-37%) | — | WordPressMySQLRedis+44 | 7 patents Computational genomics and protein modeling software for sequence assembly and structure prediction | 3 launchs |
| 13 | Invenra Pioneering bispecific and trispecific antibody discovery and development for novel therapies | $21M | 92 mo ago | Series A | 97 97 → 57 (-41%) | — | — | 79 patents Engineering multispecific antibody constructs and heterodimerization platforms for therapeutic proteins. | — |
| 14 | EraGen Biosciences Molecular Reagent Products and molecular diagnostic products for early detection and monitoring of cancer… | $21M | 213 mo ago | Acquired | 50 | — | — | 49 patents Patents concentrated in chemistry & materials | — |
| 15 | BioSentinel Innovative BoNT detection and potency testing solutions for biodefense and pharmaceutical applications | $21M | 176 mo ago | Funding Raised | 16 | — | — | 14 patents FRET-based protease assays for botulinum toxin detection and related enzymatic screening | — |
| 16 | TomoTherapy Developer of radiation therapy system for the treatment of various types of cancers | $18M | 267 mo ago | Acquired | 107 | Thomas Rock Co-Founder | — | 259 patents Patents concentrated in health & consumer products | — |
| 17 | Brainxell Neural stem cells and progenitor cells for life science research | $16M | 34 mo ago | Series B | 37 | Su Chun Zhang Founder | — | 8 patents Manufacturing stem‑cell derived dopaminergic and spinal GABAergic neuronal progenitors | 1 launch |
| 18 | NorthStar Medical Radioisotopes Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market | $15M | 13 mo ago | Series B | 305 | — | WordPressMySQLPHP+18 | — | 2 job openings · 1 partnership |
| 19 | InvivoSciences Precision medicine company personalizing drug development with 3D micro-tissue technology | $15M | 45 mo ago | Funding Raised | 6 | — | — | 20 patents Automated 3D cardiac tissue and stem‑cell culture platforms for drug screening and therapy | — |
| 20 | Allergy Amulet Developer of a portable food allergen sensor for sample detection 42Moat top 31%Tech top 33%Growth top 35%Funding top 40% All 10 signals ▾Moattop 31% Techtop 33% Growthtop 35% Fundingtop 40% Producttop 46% Talentbottom 49% Innovationbottom 47% Patentsbottom 35% Globalbottom 31% Marketbottom 27% Moat: Editorial + unicorn rating 7/10 · IP moat: 11 patents Tech: 38 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 42/100 | $13M | 22 mo ago | Series A | 18 | Joseph BelBruno Co-Founder | Squarespace CommerceSquarespaceProton Mail+30 | 11 patents Electropolymerized biosensors for rapid food allergen detection and quantification. | — |
| 21 | Atterx Biotherapeutics Developing novel solutions to prevent and treat antibiotic-resistant bacterial infections | $12M | 122 mo ago | Series A | — | Steve Watt CEO | — | 8 patents Live bacterial therapeutics and small-colony variants for wound and surface healing | — |
| 22 | OnLume Developer of smart devices for fluorescence image-guided surgery | $12M | 41 mo ago | Series A | 26 | Andreas Velten Co-Founder | — | 6 patents Low-light video capture and multi-wavelength imaging technologies for dim environments | — |
| 23 | Stemina Biomarker Discovery Human in vitro toxicity testing for drug, food, and product safety | $11M | 120 mo ago | Series A | 14 | — | — | 78 patents Metabolomic biomarker assays for cardiotoxicity, developmental toxicity, and autism diagnostics | — |
| 24 | Madison Vaccines Developer of immunotherapies for the treatment of prostate cancer | $11M | 135 mo ago | Series A | — | Richard Lesniewski Co-Founder & CEO | — | 20 patents Prostate cancer immunotherapy vaccines combining PAP antigen with PD‑1 blockade | — |
| 25 | Nimble Therapeutics Provider combinatorial chemistry-related drug discovery services | $10M | 85 mo ago | Acquired | 24 | — | — | — | — |
| 26 | Gregor Diagnostics Provider of non-invasive screening test for prostate cancer | $7M | 8 mo ago | Series A | 12 | Steven Weinstein CEO | — | — | — |
| 27 | Platypus Technologies Provider of custom metal, optical, and patterned thin film coatings | $7M | 52 mo ago | Early Stage | 10 | — | WordPressMySQLPHP+22 | 88 patents UAV aerial imaging, surveillance, and data indexing; rock-climbing safety hardware solutions. | — |
| 28 | Mirus Bio Developer of transfection reagents and electroporation products | $7M | 213 mo ago | Acquired | 33 33 → 63 (+91%) | — | WordPressSalesforceSalesforce Service Cloud+30 | — | — |
| 29 | Centrose Developing next-generation Extracellular Drug Conjugates (EDCs) for targeted cancer therapies | $7M | 81 mo ago | Series A | 12 | James Prudent President & CEO | — | 13 patents Antibody‑drug conjugates for extracellular CD20‑targeted cancer therapy | — |
| 30 | PhylloTech Biotechnology company providing protein products for research use, including cytokines and other products | $6M | 12 mo ago | Funding Raised | 2 | Colin Shepherd Co-Founder & COO | — | — | — |
| 31 | Stem Pharm Engineering human biology for neurologic drug discovery with advanced in vitro models | $6M | 6 mo ago | Funding Raised | 10 | — | Cart FunctionalitySquarespace CommerceSquarespace+9 | — | — |
| 32 | Semba Biosciences Provider of systems for molecular separation based on simulated moving bed chromatography (SMBC) | $6M | 90 mo ago | Acquired | 13 | — | — | 38 patents High‑flow industrial fluid control valve blocks for enhanced fluid handling systems | — |
| 33 | AIQ Solutions AIQ Global: Optimizing late-stage cancer care with technology-enabled service | $6M | 3 mo ago | Series A | 25 25 → 21 (-16%) | Glenn Liu Co-Founder & Chief Medical Officer | WordPressMySQLPHP+18 | 22 patents Clinical decision-support tools for lesion monitoring and treatment side‑effect assessment | — |
| 34 | Madeline Pharmaceuticals Developing formulated renopeptins for cardiorenal diseases | $5M | 121 mo ago | Funding Raised | — | Tom Geimer Co-Founder & CEO | — | — | — |
| 35 | AmebaGone Novel technology fighting antimicrobial resistance with amoebae to control pathogenic microbes | $4M | 68 mo ago | Funding Raised | 6 | Marcin Filutowicz Founder | — | 17 patents Live amoeba-based therapeutics and anti‑biofilm microbial agents for medical applications | — |
| 36 | Atrility Medical AI-powered cardiac monitoring for clearer decisions and improved patient care 24Innovation top 40%Funding top 43%AI top 45%Talent top 45% All 8 signals ▾Innovationtop 40% Fundingtop 43% AItop 45% Talenttop 45% Producttop 46% Techbottom 30% Globalbottom 29% Marketbottom 15% Innovation: 2 product lines Funding: Raised $3.4M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $3M | 7 mo ago | Series A | 8 | Nick Bergen Co-Founder | — | — | — |
| 37 | Neurosetta Provider of human stem cell-derived platform for high-throughput modeling of human brain and spinal cord… | $3M | 13 mo ago | Funding Raised | — | Randolph Ashton Co-Founder & CEO | — | — | — |
| 38 | Flex Biomedical Developing novel orthopedic treatments and diagnostics for injuries and diseases | $3M | 168 mo ago | Seed | 2 | Sal Braico Ex-CEO | — | — | — |
| 39 | Swallow Solutions Devices for diagnosing and treating dysphagia through oropharyngeal strengthening | $3M | 108 mo ago | Series A | 4 | — | — | 16 patents Protein beverage formulation and swallowing assessment/improvement technologies. | — |
| 40 | Proteovista Provider of bioinformatics services and DNA-binding assay development | $3M | 39 mo ago | Funding Raised | 5 | Mary Ozers Co-Founder | — | 4 patents High-throughput SNP genotyping microarray technology for genetic analysis | — |
| 41 | Dianomi Therapeutics Developer of therapies for treating inflammatory diseases | $3M | 69 mo ago | Series A | 7 | — | — | — | — |
| 42 | Salus Discovery Molecular diagnostics innovator creating impactful solutions for real-world problems | $2M | 13 mo ago | Funding Raised | 16 | Dave Beebe CEO & President | — | 56 patents Microfluidic bioseparation platforms for target isolation and stable interface chemistries. | — |
| 43 | Immuto Scientific Digital drug discovery tool for reserchers | $2M | 56 mo ago | Seed | 7 | Daniel Benjamin Co-Founder | Framer SitesApple iCloud MailMicrosoft 365+11 | — | — |
| 44 | Isomark Breath analyzer for infectious disease detection | $2M | 41 mo ago | Series A | 10 | Joe Kremer CEO | — | — | — |
| 45 | Calimetrix Provides solution for magnetic resonance quantification | $2M | 36 mo ago | Funding Raised | 7 | — | — | — | 2 awards |
| 46 | BellBrook Labs Specialty company engaged in drug discovery and biological research by providing screening solutions for… | $2M | 21 mo ago | Seed | 18 | Robert Lowery President & CEO | Cart FunctionalityWooCommerceWordPress+14 | 56 patents Small-molecule cGAS inhibitors for immunotherapy and inflammatory disease treatment | — |
| 47 | Origami Surgical Developer of robotic-assisted surgery devices for surgeons | $1M | 11 mo ago | Seed | 5 | Patrick Culligan Founder / CMO | — | — | — |
| 48 | DiagMetrics Provider of mask-based diagnostic system to detect COVID-19 | $939K | 34 mo ago | Funding Raised | — | Shekhar Wadekar Co-Founder | — | 11 patents Patents concentrated in health & consumer products | — |
| 49 | Cellular Logistics Acellular biomaterials for cardiac and tissue vascularization applications | $743K | 14 mo ago | Seed | 9 | Amish Raval Board Chairman and Founder | — | — | — |
| 50 | Otologic Technologies Developer of an AI-enabled diagnostic device for detecting ear diseases | $645K | 44 mo ago | Seed | 5 | Dan Wenger CEO | — | — | — |
Top 12 Life Sciences companies in Madison
#1
Series C · Madison, Wisconsin · founded 2010 · 35 employees$34.3Mraised▾
Provider of nanotech-based wound care products. The company has developed technologies for embedding bioactive molecules in wound dressings and surgical implants. The products are based on the Microlyte Matrix technology platform. The company also offers antibacterial, anti-biofilm, and analgesic wound dressings.
- Jan 2026Series C—
- Jan 2024Convertible Debt$10M
- Dec 2023Series B$3.5M
- May 2023Series B$2.5M
#2
Series A · Madison, Wisconsin · founded 2016 · 25 employees$5.5Mraised▾
AIQ Global: Optimizing late-stage cancer care with technology-enabled service. This is a technology company focused on improving treatment outcomes for late-stage cancer patients. They address a poorly served stage of the cancer patient journey by providing a software medical device, TRAQinform IQ, that offers novel information about the quantification of change in regions of interest over time. Oncologists/clinicians use this technology to more precisely adjust therapies and optimize clinical outcomes. The software integrates easily into existing workflows, utilizing serial radiographic images uploaded via the cloud to provide quantitative and spatial information. This enables oncologists to tailor treatment regimens and optimize outcomes based on a comprehensive report. The company is committed to innovation and clinical validation, aiming to change how clinicians manage complex diseases. This is a B2B SaaS company in the healthcare sector.
- Mar 2026Series A$1.4M
- Jul 2025Series A$1.6M
- May 2024Series A$2.3M
- Aug 2019Series A$3.2M
#3
Series B · Madison, Wisconsin · founded 2018$45.1Mraised▾
AI-powered automated robotic surgery device for dentists. The company combines novel imaging technology with AI and surgical robotics to automate surgery in dental industry.
- Aug 2025Grant (prize money)$1.7M
- Jul 2025Series B—
- Jul 2024Series B$30M
- Sep 2023Grant (prize money)$1.7M
#4
Funding Raised · Madison, Wisconsin · founded 2015 · 10 employees$5.9Mraised▾
Engineering human biology for neurologic drug discovery with advanced in vitro models. This company specializes in physiologically relevant human neural organoids featuring microglia for neuroimmune drug discovery. They offer comprehensive drug discovery services and partnerships, including neurologic disease modeling, target discovery, phenotypic drug screening, and neurotoxicity assessments. They also provide synthetic substrates, such as chemically-defined hydrogels and pre-coated cell culture plates, to improve outcomes for cell-based applications. Their team of experienced scientists designs and executes studies to generate new insights, supporting the movement to reduce animal testing in drug development. They focus on advancing research in areas like Alzheimer’s disease and neuroinflammatory diseases through innovative in vitro models.
- Dec 2025Grant (prize money)$406.5K
- Sep 2024Grant (prize money)$500K
- Sep 2023Grant (prize money)$554.9K
- Jul 2023Grant (prize money)$406.5K
#5
Series A · Madison, Wisconsin · founded 2016 · 12 employees$7.2Mraised▾
Provider of non-invasive screening test for prostate cancer. The company's proprietary assay analyzes seminal fluid for the presence of eight cancer-associated biomarkers that may be missed in blood or urine-based tests. The assay will stratify patients into no cancer, indolent cancer, and aggressive cancer levels. Patients can receive an at-home sample collection kit and send it to the company for analysis.
- Oct 2025Series A$242K
- Nov 2023Conventional Debt$6M
- Mar 2023Series A$7.4M
- Oct 2019Seed$915.7K
#6
Funding Raised · Madison, Wisconsin · founded 1984 · 41 employees$22Mraised▾
Provider of software for genomics, structural biology, and clinical research. The solutions include DNASTAR Lasergene Suite for genomics, structural biology, and molecular biology research, Molecular Biology Suite which can be used for multiple and pairwise sequence alignments, identify genes, assemble contigs of Sanger sequences, create clones, and other services.
- May 2025Grant (prize money)$6M
- Aug 2023Grant (prize money)$1.3M
- May 2020Grant (prize money)$5M
- Apr 2020Grant (prize money)$1.5M
#7
Series A · Madison, Wisconsin · founded 2017 · 8 employees$3.4Mraised▾
AI-powered cardiac monitoring for clearer decisions and improved patient care. This company is focused on transforming bedside monitoring through its innovative AtriRhythm AI platform and AtriAmp device. They provide solutions for critical care arrhythmia monitoring, addressing challenges in post-operative settings. Their technology facilitates continuous atrial electrogram monitoring, aiding in the diagnosis and treatment of atrial arrhythmias. The AI platform offers real-time component recognition, retrospective signal labeling, and literature-based interval mapping, providing clinicians with verifiable clinical insights. They are dedicated to improving cardiac health and patient outcomes through advances in medical technology, integrating healthcare, business, and engineering expertise. Their focus is on cardiac medical devices, atrial electrogram, arrhythmia monitoring, AI, and patient care.
- Nov 2025Series A$1M
- Sep 2024Grant (prize money)$275K
- Jun 2022Series A$3.4M
- Sep 2020Conventional Debt$300K
#8
Series B · Madison, Wisconsin · founded 2006 · 305 employees$15.1Mraised▾
Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market. Its patented technologies include innovative non-uranium-based molybdenum-99 production methods, a novel separation chemistry system, and tools for the nuclear medicine market. Products include Non-HEU 99-Molybdenum and RadioGenix intelligent isotope separation system. Claims to be the first domestic producer of 99-Molybdenum and the only supplier of Non-HEU material.
- May 2025Grant (prize money)$10.7M
- Jul 2019Grant (prize money)$15M
- Apr 2019Conventional Debt$75M
- Oct 2015Grant (prize money)$11.8M
#9
Funding Raised · Madison, Wisconsin · founded 2009 · 2 employees$6.1Mraised▾
Biotechnology company providing protein products for research use, including cytokines and other products. It is a biotechnology company that specializes in developing and manufacturing endotoxin-free protein products for research use. The company offers a growing catalog of RUO cytokines and other products for sale, catering to the needs of research institutions and organizations. Its products are used in various applications, including biopesticides, plant-based pharmaceuticals, and medical research.
- May 2025Grant (prize money)$1M
- Jun 2020Grant (prize money)$256K
- Feb 2020Grant (prize money)$1.1M
- Sep 2016Grant (prize money)$916K
#10
Funding Raised · Madison, Wisconsin · founded 2002 · 16 employees$25.9Mraised▾
Developer of bioengineered E.coli strains for a range of applications. The company has developed clean genome E. coli, a unique, patented set of bacterial hosts for reliable, high-efficiency production of protein and nucleic acid biopharmaceuticals. The product line includes vaccine carrier proteins, vectors, and diagnosis kits.
- Sep 2024Grant (prize money)$842.2K
- Jul 2020Grant (prize money)$2.9M
- Jan 2019Grant (prize money)$1.8M
- Dec 2016Grant (prize money)$1.7M
#11
Funding Raised · Madison, Wisconsin · founded 2018$3.4Mraised▾
Provider of human stem cell-derived platform for high-throughput modeling of human brain and spinal cord development. The platform utilizes human stem cell-derived arrays, known as RosetteArrays, to model early human brain and spinal cord development, enabling the discovery of potential toxic compounds.
- May 2025Grant (prize money)$1.7M
- Jan 2022Grant (prize money)$1.7M
#12
Series A · Madison, Wisconsin · founded 2016 · 18 employees$12.6Mraised▾
Developer of a portable food allergen sensor for sample detection. The device allows users to test food samples for the presence of allergenic ingredients. It is designed to detect allergens at levels that could trigger reactions. The sensor pairs with an application to track results.
- Aug 2024Series A$5.8M
- Jan 2022Grant (prize money)—
- Mar 2021Seed$800K
- Aug 2020Seed$3.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Madison is moving
A read on the academic research around Biotechnology in Madison — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 75 papers.
University of Wisconsin–Madison leads Madison's biotech research, focusing optimistically on genetic mapping, biofuels, and cancer mechanisms, with recent output tripling earlier work.
- University of Wisconsin–Madison72
- Madison Group3
- James Madison University2
- In vivo3
- Genome3
- Flow cytometry2
- Transcription factor2
- Downregulation and upregulation2
- Selection (genetic algorithm)4
- Gene3
- Quantitative trait locus3
- Messenger RNA2
- Plant breeding2
- Agriculture3
- Metagenomics2
- Dairy cattle2
- Ploidy1
- Mutation1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.